BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.1% – Here’s Why

Posted by Logan Wallace on Apr 25th, 2026

BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report)’s stock price traded up 0.1% on Friday . The company traded as high as $1.7050 and last traded at $1.6620. 2,994 shares traded hands during trading, a decline of 72% from the average session volume of 10,534 shares. The stock had previously closed at $1.66.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Check Out Our Latest Analysis on BeyondSpring

BeyondSpring Trading Up 0.1%

The firm has a market cap of $68.34 million, a P/E ratio of -11.08 and a beta of 0.51. The company’s 50-day moving average is $1.58 and its two-hundred day moving average is $1.73.

BeyondSpring (NASDAQ:BYSI – Get Free Report) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.49.

Hedge Funds Weigh In On BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC grew its position in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 951.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 256,212 shares of the company’s stock after acquiring an additional 231,844 shares during the quarter. Geode Capital Management LLC owned 0.64% of BeyondSpring worth $603,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 40.29% of the stock is owned by institutional investors and hedge funds.

About BeyondSpring

(Get Free Report)

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.